A5012517099- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Genetic factors in colorectal cancer
- Gastric Cancer Management and Outcomes
- Cancer Genomics and Diagnostics
- Nutrition and Health in Aging
- Gastrointestinal Tumor Research and Treatment
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Frailty in Older Adults
- Childhood Cancer Survivors' Quality of Life
- Chemotherapy-related skin toxicity
- COVID-19 and healthcare impacts
- Cancer survivorship and care
- HER2/EGFR in Cancer Research
- Oral health in cancer treatment
- COVID-19 Clinical Research Studies
- Neuroendocrine Tumor Research Advances
- Colorectal Cancer Surgical Treatments
- Chronic Lymphocytic Leukemia Research
- Drug-Induced Adverse Reactions
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Treatments and Mutations
- Esophageal Cancer Research and Treatment
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Institut Jean Godinot
2017-2025
Centre Hospitalier Universitaire de Reims
2017-2025
Université de Reims Champagne-Ardenne
2017-2025
Pôle de Recherche pour l'Organisation et la Diffusion de l'Information Géographique
2023-2024
Cancer Institute (WIA)
2022
Hôpital Robert-Debré
2019
PURPOSE GEMPAX was an open-label, randomized phase III clinical trial designed to assess the efficacy and tolerability of gemcitabine plus paclitaxel versus alone as second-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who previously received 5-fluorouracil, oxaliplatin, irinotecan. METHODS Patients histologically or cytologically confirmed mPDAC were randomly assigned (2:1) receive (paclitaxel 80 mg/m 2 + 1,000 ; IV; once at day (D) 1, D8, D15/arm A)...
Only 1 randomized clinical trial has shown the superiority of immune checkpoint inhibitors in patients with deficient mismatch repair and/or microsatellite instability (dMMR/MSI) metastatic colorectal cancer (mCRC) first-line setting.To determine whether avelumab (an anti-programmed cell death ligand antibody) improves progression-free survival (PFS) compared standard second-line chemotherapy dMMR/MSI mCRC.The SAMCO-PRODIGE 54 is a national open-label phase 2 that was conducted from April...
Abstract Background FIGHTDIGO study has shown the feasibility of handgrip strength (HGS) measurements in 201 consecutive digestive cancer patients undergoing chemotherapy. Objective This focuses on a secondary aim study: relationship between muscle mass and HGS. Design Two bilateral measures HGS were performed using Jamar dynamometer before start each The highest value was chosen for final evaluation. Dynapenia (loss strength) defined as < 30 kg (men) 20 (women). Muscle measured at lumbar...
The COVID-19 pandemic has been associated with substantial reduction in screening, case identification, and hospital referrals among patients cancer. However, no study quantitatively examined the implications of this correlation for cancer patient management.
Dihydropyrimidine dehydrogenase (DPD) deficiency screening is a pre-therapeutic standard to prevent severe fluoropyrimidine-related toxicity. Although several methods exist, the accuracy of their results remains debatable. In France, uracilemia measurement considered in DPD screening. The objective this study was describe hyperuracilemia (⩾16 ng/mL) rate and investigate influence hepatic renal impairment measurements since guidelines were implemented.Using cohort 1138 patients screened...
FIGHTDIGO study showed the feasibility and acceptability of handgrip strength (HGS) measure in routine 201 consecutive patients with digestive cancer treated ambulatory chemotherapy. The present focuses on second aim study: relationships between pre-therapeutic dynapenia chemotherapy-induced Dose-Limiting Toxicities (DLT).In this ancillary prospective study, DLT were analyzed a sub-group 45 chemotherapy-naive patients. Two bilateral measures HGS performed Jamar dynamometer before first cycle...
Low skeletal muscle mass and impaired quality (myosteatosis) have been associated with poor outcomes in cancer patients. This study aimed to evaluate the impact of pre-therapeutic low myosteatosis on chemoradiotherapy (CRT)-induced toxicity survival patients non-resectable pancreatic (PC). In this retrospective study, CT scans were used measure mass/density. was defined as a index <38.5 cm²/m² (women) <52.4 (men), mean psoas density <41 HU if BMI < 25 kg/m² or <33 > kg/m². Adverse effects...
ABSTRACT Background Colorectal cancer (CRC) is the second leading cause of cancer‐related death worldwide. The French CRC screening campaign based on fecal immunochemical tests (FIT), confirmed by colonoscopy, an invasive procedure with a poor participation rate. This study aimed to compare expression circulating exosomal proteins (MMP14, β1‐Integrin subunit, β3‐Integrin and α1(I) Collagen chain) in patients or adenomas. Methods A total 71 were recruited, including 24 controls (normal...
Several options have been evaluated in metastatic gastro-oesophageal adenocarcinomas (mGA) after failure of first-line fluoropyrimidine and platinum-based chemotherapy. Regorafenib (REGO), a receptor tyrosine kinase inhibitor, has shown promising activity as second- third-line treatment mGA. PRODIGE58-UCGI35-REGIRI was comparative, prospective, phase II, open-label study evaluating the safety efficacy REGO [160 mg/day on day 2 (D2)-D8/D16-D22] plus irinotecan (IRI: 180 mg/m2 intravenously...
Dihydropyrimidine dehydrogenase (DPD) deficiency is associated with severe fluoropyrimidines-induced toxicity. As of September 2018, French recommendations call for screening DPD by plasma uracil quantification prior to all fluoropyrimidine-based chemotherapy. A dose reduction fluoropyrimidine recommended when concentration equal or greater than 16 ng/mL. This matched retrospective study assessed the impact on side effects and management DPD-deficient patients. Using a propensity score, we...
BACKGROUND Handgrip strength (HGS) is a widely studied noninvasive test. Weak (dynapenia) seems to be associated with high morbidity and mortality in different populations, notably oncology populations. Despite this, HGS testing not used daily practice oncology. The study was aimed at evaluating the feasibility acceptability of patients digestive cancer treated ambulatory chemotherapy. METHODS In this prospective, single‐center study, enrolled were followed for 6 months. Two consecutive...
Abstract After failure of first line FOLFOX‐bevacizumab for metastatic colorectal cancer (mCRC), adding either bevacizumab or aflibercept to second‐line FOLFIRI increases survival compared alone. In this French retrospective multicentre cohort, we included patients with a mCRC treated FOLFIRI‐aflibercept FOLFIRI‐bevacizumab. The primary endpoint was overall (OS), and secondary endpoints were progression‐free (PFS), disease control rate (DCR: CR + PR SD) safety. We 681 from 36 centers, 326...
Efficacy of immune checkpoint inhibitors (ICI) as monotherapy in 2nd line treatment for gastric or gastro-oesophageal junction (GEJ) adenocarcinoma is low, with no evaluation efficacy and safety ICI combined chemotherapy. The DURIGAST PRODIGE 59 study a randomised, multicentre, phase II designed to assess the combination FOLFIRI + Durvalumab +/- Tremelimumab patients advanced gastric/GEJ adenocarcinoma. Here, we report data from run-in (arm A) B). Among 11 included, 63.6% experienced at...
Abstract Background Knowledge about environmental pancreatic adenocarcinoma (PA) risk factors, including pesticide exposure, remains limited. Organochlorine (OC) accumulates in adipose tissue and can help reflect long‐term exposure. Patients Methods Age body mass index (BMI) of patients with PA were matched those undergoing a surgery for benign disease on age BMI (1:1). Targeted analyses screened 345 pesticides metabolites, 29 OC, urine samples. The primary aim was to investigate the...
Introduction: Preclinical studies have demonstrated the possible role of beta-adrenergic receptors in pancreatic ductal adenocarcinoma (PDAC) tumor invasion and migration. The current study aimed to explore association between survival outcomes beta-blocker (BB) exposure patients with advanced PDAC. Methods: This retrospective single-center included 182 Clinical [age, sex, BMI, cardiovascular condition, presence (SBB) or absence (NSBB) beta-1 selectivity BB, duration, multimorbidity],...
Abstract Background: Previous studies have observed an increased incidence of Cetuximab-induced hypersensitivity infusion reactions (CI-IRs) in the southeastern states USA. Tick’s bites were suspected generating cross-reactions between cetuximab and alpha-gal. This study aims was to describe associated risk factors CI-IRs, French areas chosen according their Lyme disease incidence. Patients methods: A retrospective chart review conducted on patients that received from January 2010 June 2019...
The COVID-19 pandemic led to a widely documented disruption in cancer care pathway. Since resurgence of the was expected after first lockdown France, global impact on pathway over year 2020 investigated. This study aimed describe changes oncology for screening, diagnosis, assessment, diagnosis annoucement procedure and treatment one-year period. ONCOCARE-COV comprehensive, retrospective, descriptive, cross-sectional comparing years 2019 2020. All key indicators along assessing oncological...